SingleB® Hybridoma Protein Expression

Alpaca SingleB® VHH Discovery Service

Compared with conventional IgG molecules, VHH antibodies that derive from camelid heavy chain only antibodies (HCAbs) possess many unique and favorable properties of size, solubility, stability, immunogenicity, recognition of uncommon or hidden epitopes, format engineering and manufacturability, and have manifested medical potential both as diagnosis reagents and in therapeutic drug development.

Phage display is the dominant approach for VHH antibody discovery. Unfortunately, its capability is heavily subject to antibody expression bias, protein folding errors, low screening efficiency, and loss of diversity.

DetaiBio alpaca SingleB® VHH discovery platform is an excellent alternate. Armed with our SmartFlow® FACS mAb Discovery platform and DeepLight® screening technology, DetaiBio R&D team is experienced in providing SingleB® Alpaca VHH antibody fast discovery service: we are able to deliver certain amount of unique, FACS-validated VHH antibody candidates as fast as 90 days after 1st immunization shot. Similar with our cases of other host species, before us losing them, both memory B cells and plasma cells are directly screened to cover most B cell clones, thus guaranteeing maximal CDR diversity of antibody hits.

VHH Features

Conventional antibody

Camelid heavy-chain antibody



Based on its structural specificity, VHH integrates the advantages of traditional antibodies and small molecule drugs:

  • Low Molecular Weight: only 12-14 kda with strong tissue penetration, widely used in tumor diagnosis and treatment and molecular imaging.
  • Simple Structure: easy to carry out genetic engineering transformation, with 80% homology with human VH and easy to humanize.
  • Low Immunogenicity: no FC tail end, which will not cause related immunogenicity, and has high pharmaceutical properties.
  • High Specificity: long CDR3 region , which can form a finger shaped convex ring to further identify hidden antigen epitopes.
  • High Hydrophilicity: hydrophilic amino acids in FR2 area ensure water solubility, and antibodies are not easy to aggregate.
  • Simple Preparation: it can be expressed in large quantities, and the industrial scale-up production cost is low and the cycle is short.
  • High Stability: it is easy to store and can withstand high temperature, strong acid, strong alkali and other mutagenic conditions.

Service Features

90-day High Delivery

Deliver 50 FACs binders
& VHH sequence

“1+1”Double Guarantee

double screening, double guarantee

Pre-function Screening

DeepLight® Platform
with multiple on-chip assay

Natural Maturation

Higher antibody affinity
Basically eliminate immunogenicity



Stage Ⅰ Animal Immunization
  • Antigen preparation (optional)
  • Animal immunization
  • Serum titer test
8-9 weeksPremium Package

  • FACs binders >50
  • Ensure sequence diversity
  • Antibody sequence and expression plasmid
  • CoA

Economic Package

  • 5-10 ELISA positive clones
  • Antibody sequence and expression plasmid
  • Select one strain purified 1 mg antibody
  • CoA
Stage Ⅱ “1+1”Double Screening
  • MBC screening
  • PBC screening
1 day
Stage Ⅲ BGE® HTP Expression & Functional Test
  • ELISA Assay
  • FACs Assay
1-2 weeks
Stage Ⅳ Monoclonal Antibody Gene Sequencing
  • HTP gene screening
1 week
Stage Ⅴ
Expression and Purification of Recombinant Antibody (optional)
  • Transfection level plasmid preparation
  • Transient transfection expression
  • HTP purification
  • Endotoxin control
For enquiry

Related Service